Asset Details
Do you wish to reserve the book?
Basic Science and Pathogenesis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Basic Science and Pathogenesis
Do you wish to request the book?
Basic Science and Pathogenesis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Basic Science and Pathogenesis
2024
Overview
Genetic, cell biology and autopsied brain tissue studies indicate that deficits in the SORL1-retromer complex play a critical role in the pathogenesis of Alzheimer's disease (AD). SORL1 is an endosomal receptor that interacts with the retromer heterotrimer core complex consisting of VPS26-VPS35-VPS29. Together, SORL1-retromer regulate endosomal recycling of several AD-related cargos such as amyloid precursor protein. In cell and animal models, deficits in SORL1 or retromer core levels recapitulate the prototypical biomarker signature and cytopathology of AD. Thus, restoration of SORL1-retromer recycling function offers an attractive therapeutic opportunity to slow or stop the progression of AD. This talk will detail a multi-modality drug development strategy founded on precision neurology principles. Specifically, there will be a discussion on small molecules and gene therapy drug development programs targeting SORL1 and/or the retromer core as well as a comprehensive biomarker strategy that has been integrated into the programs to de-risk and facilitate clinical drug development.
